{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"90.7","upperLimit":"96.1","value":"93.8"},{"groupId":"OG001","lowerLimit":"94.2","upperLimit":"98.2","value":"96.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"354"},{"groupId":"OG001","value":"355"}],"units":"Participants"}],"description":"ORR- percentage of participants who achieved partial response (PR) or better (PR, Very Good Partial Response \\[VGPR\\], CR or sCR) based on computerized algorithm as per IMWG 2011 criteria. PR -greater than or equal to (\\>=) 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \\>=90% or to \\<200 mg//24 hours. If serum and urine M-protein are not measurable, a decrease of \\>=50% in the difference between involved and uninvolved FLC levels is required. A \\>=50% reduction in the size of soft tissue plasmacytomas is also required; VGPR-serum and urine M-component detectable by immunofixation but not on electrophoresis, or \\>= 90% reduction in serum M-protein plus urine M-protein \\<100 mg/24 hours; CR-negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and \\<5% PCs in bone marrow. sCR- in addition to CR a normal FLC ratio, and absence of clonal PCs by immunohistochemistry or immunofluorescence or 2 to 4-color flow cytometry.","dispersionType":"95% Confidence Interval","groups":[{"description":"Arm A: Patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation were treated with bortezomib, lenalidomide, and dexamethasone for induction and consolidation followed by lenalidomide maintenance in 28-day cycles. After 4 cycles of induction, patients received high dose therapy with autologous stem cell transplantation.","id":"OG000","title":"Velcade Lenalidomide Dexamethasone (VRd)"},{"description":"Arm B: Patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation were treated with subcutaneous daratumumab in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation followed by subcutaneous daratumumab in combination with lenalidomide maintenance in 28-day cycles. After 4 cycles of induction, patients received high dose therapy with autologous stem cell transplantation.","id":"OG001","title":"Daratumumab + VRd (D-VRd)"}],"paramType":"NUMBER","populationDescription":"The intent-to-treat (ITT) population included all randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization to the clinical cutoff date. Maximum follow up was 54.41 months","title":"Percentage of Participants With Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"percentage of participants with response"}